Abstract:Background and PurposeNeuropeptide FF (NPFF) behaves as an endogenous opioid‐modulating peptide. In the present study, the opioid and NPFF pharmacophore‐containing chimeric peptide BN‐9 was synthesized and pharmacologically characterized.Experimental ApproachAgonist activities of BN‐9 at opioid and NPFF receptors were characterized in in vitro cAMP assays. Antinociceptive activities of BN‐9 were evaluated in the mouse tail‐flick and formalin tests. Furthermore, its side effects were investigated in rotarod, antinociceptive tolerance, reward and gastrointestinal transit tests.Key ResultsBN‐9 acted as a novel multifunctional agonist at μ, δ, κ, NPFF1 and NPFF2 receptors in cAMP assays. In the tail‐flick test, BN‐9 produced dose‐related antinociception and was approximately equipotent to morphine; this antinociception was blocked by μ and κ receptor antagonists, but not by the δ receptor antagonist. In the formalin test, supraspinal administration of BN‐9 produced significant analgesia. Notably, repeated administration of BN‐9 produced analgesia without loss of potency over 8 days. In contrast, repeated i.c.v. co‐administration of BN‐9 with the NPFF receptor antagonist RF9 produced significant antinociceptive tolerance. Furthermore, i.c.v. BN‐9 induced conditioned place preference. When given by the same routes, BN‐9 had a more than eightfold higher ED50 value for gastrointestinal transit inhibition compared with the ED50 values for antinociception.Conclusions and ImplicationsBN‐9 produced a robust, nontolerance‐forming analgesia with limited inhibition of gastrointestinal transit. As BN‐9 is able to activate both opioid and NPFF systems, this provides an interesting approach for the development of novel analgesics with minimal side effects.

Multitarget μ-Opioid Receptor Agonists─Neuropeptide FF Receptor Antagonists Induce Potent Antinociception with Reduced Adverse Side Effects

Structure-Based Optimization of Multifunctional Agonists for Opioid and Neuropeptide FF Receptors with Potent Nontolerance Forming Analgesic Activities.

Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-Lasting, and Peripherally Restricted Antinociception with Diminished Side Effects

All-Hydrocarbon Stapled Peptide Multifunctional Agonists at Opioid and Neuropeptide FF Receptors: Highly Potent, Long-Lasting Brain Permeant Analgesics with Diminished Side Effects.

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

OFP011 Cyclic Peptide as a Multifunctional Agonist for Opioid/Neuropeptide FF Receptors with Improved Blood-Brain Barrier Penetration

Pharmacological Characterization of 17-Cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) As a Dual Selective MOR/KOR Ligand with Potential Applications in Treating Opioid Use Disorder.

Synthesis, Biological Activity and Molecular Docking of Chimeric Peptides Targeting Opioid and NOP Receptors

Design, Synthesis, and In Vitro Characterization of Proteolytically-Stable Opioid-Neurotensin Hybrid Peptidomimetics

Optimization of bifunctional piperidinamide derivatives as σ1R Antagonists/MOR agonists for treating neuropathic pain

Spinal Administration of the Multi-Functional Opioid/neuropeptide FF Agonist BN-9 Produced Potent Antinociception Without Development of Tolerance and Opioid-Induced Hyperalgesia.

Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception.

BN-9, a Chimeric Peptide with Mixed Opioid and Neuropeptide FF Receptor Agonistic Properties, Produces Nontolerance-Forming Antinociception in Mice.

Synthesis and evaluation of peptide–fentanyl analogue conjugates as dual μ/δ-opioid receptor agonists for the treatment of pain

A Synthetic Peptide Exerts Nontolerance-Forming Antihyperalgesic and Antidepressant Effects in Mice

Towards multitargeted ligands as pain therapeutics: Dual ligands of the Cavα2δ‐1 subunit of voltage‐gated calcium channel and the μ‐opioid receptor

Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular Docking

Multitarget ligands that comprise opioid/nonopioid pharmacophores for pain management: Current state of the science

A Novel Bifunctional μOR Agonist and σ1R Antagonist with Potent Analgesic Responses and Reduced Adverse Effects

Multitargeted Opioid Ligand Discovery as a Strategy to Retain Analgesia and Reduce Opioid-Related Adverse Effects

Novel dual-target μ‐opioid and TRPV1 ligands as potential pharmacotherapeutics for pain management